Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Medical Excellence Capital, LLC (MEC) is an early-stage life sciences venture fund founded in 2020 and headquartered in Nissequogue, NY. The firm focuses on advancing precision health innovations through investments in transformative technologies that tackle significant medical challenges. MEC closed its inaugural fund at $145 million in August 2022, targeting investments in the United States.
The firm operates with a unique strategy that leverages a proprietary global network of physician-scientists to enhance its investment approach and support the creation of innovative companies. MEC's team comprises experienced professionals with backgrounds in healthcare venture capital, enabling them to navigate the complexities of the life sciences sector effectively.
Since its inception, MEC has established a strong presence in the life sciences investment community, actively engaging in sectors such as biotech, healthcare, artificial intelligence, and longevity. The firm is committed to addressing large unmet medical needs through its investment strategy.
MEC invests primarily in early-stage opportunities within the life sciences sector, specifically targeting company creation, seed, Series A, and Series B investments. The firm emphasizes transformative technologies that address significant medical challenges, with a particular focus on areas such as artificial intelligence in drug discovery, cell and gene therapy, precision medicine, regenerative medicine, and synthetic biology.
The typical check size ranges from $100,000 to $1.5 million, with a maximum investment ceiling of $5 million. MEC's geographic focus is primarily on the United States, with active investments in markets such as New York, California, and Pennsylvania. The firm seeks to partner with founders who are addressing large unmet medical needs and are committed to advancing precision health innovations.
MEC's active portfolio consists of seven companies, each contributing to advancements in the life sciences sector. Notable portfolio companies include:
These companies represent MEC's commitment to investing in transformative technologies that address significant medical challenges.
John Prufeta: Founder, CEO & Managing Partner. John previously served as CEO of MedEx, the predecessor organization that cultivated the physician-scientist network.
Eric Heil, MBA: Managing Partner. Eric brings extensive experience in healthcare venture capital, having previously worked at Domain Associates.
Kim Kamdar, PhD: Managing Partner. Kim has a strong background in life sciences investments and has also worked at Domain Associates.
Brian Halak, PhD: Managing Partner. Brian has a deep expertise in healthcare venture capital and has been instrumental in evaluating investment opportunities at MEC.
To pitch Medical Excellence Capital, founders should use the contact email info@medexcelcap.com. A detailed pitch deck is essential, including information about the business model, market opportunity, and team background. The firm typically responds within a few weeks, and warm introductions are preferred but not mandatory.
MEC operates the MEC Council, a network of over 1,100 physician-scientists that provides insights and expertise to evaluate investment opportunities and support portfolio companies. This program enhances the firm's ability to identify promising startups and offer strategic guidance.
In August 2022, Medical Excellence Capital announced the final close of its inaugural fund at $145 million. This milestone marked a significant achievement for the firm, enabling it to invest in early-stage life sciences companies.
Recent blog posts from MEC highlight trends in life sciences and updates on portfolio company advancements, including progress in clinical trials for Aspen Neuroscience and leadership changes at GC Therapeutics. These updates reflect the firm's active engagement in the life sciences sector and its commitment to supporting innovative companies.
What are the investment criteria for Medical Excellence Capital?
MEC focuses on early-stage life sciences companies that are addressing large unmet medical needs. The firm invests in seed, Series A, and Series B opportunities, with a particular emphasis on transformative technologies in biotech and healthcare.
How can founders apply or pitch to MEC?
Founders can pitch their startups by visiting the MEC website at medexcelcap.com and using the contact email info@medexcelcap.com. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Medical Excellence Capital different from other VCs?
MEC differentiates itself through its proprietary global network of physician-scientists, which provides unique insights and expertise in evaluating investment opportunities. The firm also has co-founding capabilities, allowing them to actively participate in the development of portfolio companies.
What is the typical check size for investments?
MEC typically invests between $100,000 and $1.5 million, with a maximum investment ceiling of $5 million. This allows them to support companies at various stages of development effectively.
What geographic areas does MEC focus on?
The firm primarily invests in the United States, with active engagement in markets such as New York, California, and Pennsylvania. This geographic focus enables MEC to leverage local networks and resources effectively.
What kind of post-investment support does MEC provide?
MEC adds value to its portfolio companies through its strong network of physician-scientists and expertise in navigating the complexities of the life sciences sector. The firm actively engages with its portfolio companies to provide strategic guidance and operational support.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.